ClinicalTrials.gg
CompletedNCT04719832SWIFT-1Updated Dec 17, 2024Results posted

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

A Phase 3 interventional study of GSK3511294 (Depemokimab) and Placebo in Asthma, sponsored by GlaxoSmithKline. Completed at 123 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
395
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing depemokimab in Asthma — 3 open to participants now, 3 under way, 3 of them phase 3. depemokimab · Asthma.

Enrollment
5th of 10
395 · median 273
Started
2021
with 3 others
Phase 3
7 of 10
3 open now
Registered
2nd of 10
by date
Lead sponsor
10 of 10
GlaxoSmithKline

Among the 10 studies testing depemokimab in Asthma, this one is the 5th largest by enrollment, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 2nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 10 studies testing depemokimab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About depemokimab

depemokimab: first FDA approval 2025 (EXDENSUR), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing depemokimab in Asthma, or all of them as a file.
02

Study summary

This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study that aims to assess the efficacy and safety of GSK3511294 (Depemokimab) in participants with severe uncontrolled asthma with an eosinophilic phenotype

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • GSK3511294 (Depemokimab)
  • Eosinophilic phenotype
  • Severe uncontrolled asthma
  • Exacerbations
  • Placebo
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion Criteria:

  • Adults and adolescents greater than or equal to (>=)12 years of age, at the time of signing the /assent.
  • Participants must have a documented physician diagnosis of asthma for >=2 years that meets the National Heart, Lung, and Blood Institute (NHLBI) guidelines or Global Initiative for Asthma (GINA) guidelines and

    1. Have, or with high likelihood of having, asthma with an eosinophilic phenotype
    2. Have previously confirmed history of >=2 exacerbations requiring treatment with systemic (CS) (intramuscular [IM], intravenous [IV], or oral), in the 12 months prior to Visit 1, despite the use of medium to high-dose ICS. For participants receiving maintenance CS, the CS treatment for the exacerbations must have been a two-fold dose increase or greater.
  • Persistent airflow obstruction as indicated by:

    1. For participants >=18 years of age at Visit 1, a pre-bronchodilator less than (\<)80% predicted (The Third National Health and Nutrition Examination Survey [NHANES III]) recorded at Visit 1
    2. For participants 12-17 years of age at Visit 1:

      • A pre-bronchodilator FEV1 \<90% predicted (NHANES III) recorded at Visit 1 OR
      • FEV1:Forced Vital Capacity (FVC) ratio \<0.8 recorded at Visit 1.
  • A well-documented requirement for regular treatment with medium to high dose ICS (in the 12 months prior to Visit 1 with or without maintenance OCS). The maintenance ICS dose must be >=440 micrograms (mcg) Fluticasone propionate (FP) Hydrofluoroalkane (HFA) product daily, or clinically comparable (GINA). Participants who are treated with medium dose ICS will also need to be treated with LABA to qualify for inclusion.
  • Current treatment with at least one additional controller medication, besides ICS, for at least 3 months (for example [e.g.], LABA, LAMA, leukotriene receptor antagonist [LTRA], or theophylline).

Key randomization inclusion criteria:

  • For blood eosinophilic count:

    1. An elevated peripheral blood eosinophil count of >=300 cells/microliter (mcL) demonstrated in the past 12 months prior to Visit 1 that is related to asthma OR
    2. An elevated peripheral blood eosinophil count of >=150 cells/mcL at Screening Visit 1 that is related to asthma.
  • Evidence of airway reversibility or responsiveness as documented by either:

    1. Airway reversibility (FEV1>=12% and 200 milliliters [mL]) demonstrated at Visit 1 or Visit 2 using the Maximum Post Bronchodilator Procedure OR
    2. Airway reversibility (FEV1>=12% and 200 mL) documented in the 24 months prior to Visit 2 (randomization visit) OR
    3. Airway hyperresponsiveness (methacholine: Provocative concentration causing a 20% fall in FEV1 [PC20] of \<8 milligrams (mg)/mL, histamine: PD20 of \<7.8 micromoles, mannitol: decrease in FEV1 as per the labelled product instructions) documented in the 24 months prior to Visit 2 (randomization visit).

Key exclusion Criteria:

  • Presence of a known pre-existing, lung condition other than asthma. This includes (but is not limited to) current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or diagnoses of emphysema or chronic bronchitis ( other than asthma) or a history of lung cancer.
  • Participants with other conditions that could lead to elevated eosinophils such as hyper-eosinophilic syndromes including (but not limited to) Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly known as Churg-Strauss Syndrome) or Eosinophilic Esophagitis.
  • A current or previous history of cancer in remission for less than 12 months prior to screening (Participants that had localized carcinoma of the skin which was resected for cure will not be excluded).
  • Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.
  • Participants with current diagnosis of vasculitis. Participants with high clinical suspicion of vasculitis at screening will be evaluated and current vasculitis must be excluded prior to enrolment.
  • Participants who have received mepolizumab (Nucala), reslizumab (Cinqair/Cinqaero), or benralizumab (Fasenra) within 12 months prior to Visit 1 or who have a previous documented failure with anti-IL-5/5 receptor (R) therapy.
  • Participants who have received omalizumab (Xolair) or dupilumab (Dupixent) within 130 days prior to Visit.
  • Participants who have received any monoclonal antibody (mAb) within 5 half-lives of Visit 1.
  • Previously participated in any study with mepolizumab, reslizumab, or benralizumab and received study intervention (including placebo) within 12 months prior to Visit 1.
  • The corrected using Fridericia's formula (QTcF) >=450 milliseconds (msec) or QTcF >=480 msec for participants with Bundle Branch Block at screening Visit 1.
  • Current smokers or former smokers with a smoking history of >=10 pack years (number of pack years = [number of cigarettes per day/20] times number of years smoked). A former smoker is defined as a participant who quit smoking at least 6 months prior to Visit 1.
  • Participants with allergy/intolerance to the of GSK3511294 or a any mAb or biologic.

Key radomization exclusion criteria:

  • QTcF >=450 msec or QTcF >=480 msec for participants with Bundle Branch Block, at randomization Visit 2 are excluded. Participants are excluded if an abnormal finding from the 12-lead ECG conducted at Screening Visit 1 is considered to be clinically significant and would impact the participant's participation during the study, based on the evaluation of the Investigator.
  • Participants with a clinically significant asthma exacerbation in the 7 days prior to randomization should have their randomization visit delayed until the investigator considers the participant's asthma to be stable .
  • Any changes in the dose or regimen of Baseline ICS and/or additional controller medication (except for treatment of an exacerbation) during the run-in period.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
395 participants (actual)

Study arms

  • Experimental
    GSK3511294

    Participants received a 100 milligram (mg) dose of GSK3511294 SC injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma SOC treatment throughout the study.

    Biological: GSK3511294 (Depemokimab)

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneous (SC) injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma standard of care (SOC) treatment throughout the study.

    Drug: Placebo

Interventions

  • GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.

  • DrugPlacebo

    Matching placebo will be administered as a normal saline using a pre-filled syringe.

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks

    Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) \[such as intramuscular (IM), intravenous (IV) or oral\] and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the electronic case report form (eCRF) were considered as verified clinically significant exacerbations and included in the primary analysis. Exacerbations separated by less than 7 days was treated as a continuation of the same exacerbation.

    Time frame: Up to Week 52

Secondary outcomes

  1. Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52

    The SGRQ is a 50-item patient-reported outcome tool used to measure Quality of Life in participants with airway obstruction diseases. The questions are designed to be self-completed by the participant. The total score was calculated by the symptom score, activity and impact score; and summarizing the impact of the disease on overall health status on 0-100 rating scale. Scores are expressed as a percentage of overall impairment where 100 representing worst possible health status and 0 indicating best possible health status. Higher scores indicating greater impairment of quality of life. Change from Baseline was defined as value at the indicated time point minus Baseline value.

    Time frame: Baseline (Day 1) and Week 52

  2. Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52

    The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma symptom control. The questions are designed to be self-completed by the participant. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated more limitations and lower score with better asthma control. Change from Baseline was defined as value at the indicated time point minus Baseline value.

    Time frame: Baseline (Day 1) and Week 52

  3. Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) At Week 52

    Forced Expiratory Volume in One Second (FEV1) is defined as the volume of air that can be forced out in one second after taking a deep breath by a person and will be measured by spirometry testing. Change from Baseline in clinic pre-bronchodilator FEV1 was determined. Change from Baseline was defined as value at the indicated time point minus Baseline value.

    Time frame: Baseline (Day 1) and Week 52

  4. Change From Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score at Week 52

    The ANSD is a 6-item self-administered patient reported diary developed by Patient Related Outcomes (PRO) Consortium's Asthma Working Group to facilitate comprehensive and reliable assessment of asthma symptoms from a participant's perspective. Participants were required to rate the severity of symptoms in 3 core categories: breathing symptoms (wheezing, shortness of breath), chest symptoms (chest tightness, chest pain) and cough. The ANSD was to be completed before going to bed and refers to asthma symptoms during the day. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (None) to 10 (As bad as you can imagine). Higher scores indicate more severe symptoms. Mean daily scores of ANSD was calculated by weekly intervals. The baseline values were defined as the average score from Day -7 to Day -1 inclusive (at least 4 days must be non-missing). Change from Baseline was defined as value at each time point minus Baseline value.

    Time frame: Baseline to Week 52

  5. Change From Baseline in Asthma Daily Symptom Diary (ADSD) Weekly Mean Score at Week 52

    The ADSD is a 6-item self-administered patient reported diary developed by patient related outcomes (PRO) Consortium's Asthma Working Group to facilitate comprehensive and reliable assessment of asthma symptoms from a participant's perspective. Participants were required to rate the severity of symptoms in 3 core categories: breathing symptoms (wheezing, shortness of breath), chest symptoms (chest tightness, chest pain) and cough. The ADSD was to be completed upon waking and refers to asthma symptoms during the night-time. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (None) to 10 (As bad as you can imagine). Higher scores indicate more severe symptoms. Mean daily scores of ADSD was calculated by weekly intervals. The baseline values were defined as the average score from Day -7 to Day -1 inclusive (at least 4 days must be non-missing). Change from Baseline was defined as value at each time point minus Baseline value.

    Time frame: Baseline to Week 52

  6. Annualized Rate of Exacerbations Requiring Hospitalization and/or Emergency Department (ED) Visit up to 52 Weeks

    The data did not meet the condition (total of 20 or more exacerbations requiring hospitalization and/or ED visit) for conducting the statistical analysis. The number of exacerbations requiring Hospitalization and/or ED Visit are reported here.

    Time frame: Up to Week 52

07

Results

Posted Dec 17, 2024

Participant flow

A total of 395 participants were randomized to the study. Of which 382 participants were included in Full analysis set (FAS) population. FAS included all randomized participants who received at least 1 dose of study intervention excluding 11 participants from 1 site with Good Clinical Practice (GCP)/data integrity issues. Two (2) participants were randomized in error and did not receive any study drug.

Participant flow — Overall Study
MilestonePlaceboGSK3511294
Started136259
Full analysis population132250
Completed122237
Not completed1422
Withdrew: Adverse event20
Withdrew: Lack of efficacy24
Withdrew: Lost to follow-up02
Withdrew: Physician decision01
Withdrew: Pregnancy11
Withdrew: Withdrawal by subject55
Withdrew: Randomized, not treated02
Withdrew: Gcp violations47

Outcome measures

PrimaryAnnualized Rate of Clinically Significant Exacerbations up to 52 Weeks

Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) \[such as intramuscular (IM), intravenous (IV) or oral\] and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the electronic case report form (eCRF) were considered as verified clinically significant exacerbations and included in the primary analysis. Exacerbations separated by less than 7 days was treated as a continuation of the same exacerbation.

Time frame:
Up to Week 52
Reported as:
Least squares mean · Exacerbation per participant per year
Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks
Exacerbation per participant per yearPlaceboGSK3511294
Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks1.11 ± 0.860.46 ± 0.36
Statistical analysis
  • Placebo vs GSK3511294 · Negative binomial distribution · p = < 0.001 · Rate ratio: 0.42 · 95% CI 0.30 to 0.59
SecondaryChange From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52

The SGRQ is a 50-item patient-reported outcome tool used to measure Quality of Life in participants with airway obstruction diseases. The questions are designed to be self-completed by the participant. The total score was calculated by the symptom score, activity and impact score; and summarizing the impact of the disease on overall health status on 0-100 rating scale. Scores are expressed as a percentage of overall impairment where 100 representing worst possible health status and 0 indicating best possible health status. Higher scores indicating greater impairment of quality of life. Change from Baseline was defined as value at the indicated time point minus Baseline value.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52
Scores on a scalePlaceboGSK3511294
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52-9.67 ± 1.544-13.03 ± 1.112
Statistical analysis
  • Placebo vs GSK3511294 · Mixed Models Repeated Measures (MMRM) · p = = 0.080 · Difference in least square means: -3.36 · 95% CI -7.11 to 0.39
SecondaryChange From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52

The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma symptom control. The questions are designed to be self-completed by the participant. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated more limitations and lower score with better asthma control. Change from Baseline was defined as value at the indicated time point minus Baseline value.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · Scores on a Scale
Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52
Scores on a ScalePlaceboGSK3511294
Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52-0.77 ± 0.091-0.82 ± 0.066
Statistical analysis
  • Placebo vs GSK3511294 · Mixed Models Repeated Measures (MMRM) · p = = 0.690 · Difference in least square means: -0.04 · 95% CI -0.27 to 0.18
SecondaryChange From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) At Week 52

Forced Expiratory Volume in One Second (FEV1) is defined as the volume of air that can be forced out in one second after taking a deep breath by a person and will be measured by spirometry testing. Change from Baseline in clinic pre-bronchodilator FEV1 was determined. Change from Baseline was defined as value at the indicated time point minus Baseline value.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · Liters (L)
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) At Week 52
Liters (L)PlaceboGSK3511294
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) At Week 520.160 ± 0.03640.160 ± 0.0263
Statistical analysis
  • Placebo vs GSK3511294 · Mixed Models Repeated Measures (MMRM) · p = = 0.991 · Difference in least square means: -0.001 · 95% CI -0.089 to 0.088
SecondaryChange From Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score at Week 52

The ANSD is a 6-item self-administered patient reported diary developed by Patient Related Outcomes (PRO) Consortium's Asthma Working Group to facilitate comprehensive and reliable assessment of asthma symptoms from a participant's perspective. Participants were required to rate the severity of symptoms in 3 core categories: breathing symptoms (wheezing, shortness of breath), chest symptoms (chest tightness, chest pain) and cough. The ANSD was to be completed before going to bed and refers to asthma symptoms during the day. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (None) to 10 (As bad as you can imagine). Higher scores indicate more severe symptoms. Mean daily scores of ANSD was calculated by weekly intervals. The baseline values were defined as the average score from Day -7 to Day -1 inclusive (at least 4 days must be non-missing). Change from Baseline was defined as value at each time point minus Baseline value.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Scores on a Scale
Change From Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score at Week 52
Scores on a ScalePlaceboGSK3511294
Change From Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score at Week 52-1.30 ± 0.168-1.39 ± 0.120
Statistical analysis
  • Placebo vs GSK3511294 · Mixed Models Repeated Measures (MMRM) · p = = 0.650 · Difference in least square means: -0.09 · 95% CI -0.50 to 0.31
SecondaryChange From Baseline in Asthma Daily Symptom Diary (ADSD) Weekly Mean Score at Week 52

The ADSD is a 6-item self-administered patient reported diary developed by patient related outcomes (PRO) Consortium's Asthma Working Group to facilitate comprehensive and reliable assessment of asthma symptoms from a participant's perspective. Participants were required to rate the severity of symptoms in 3 core categories: breathing symptoms (wheezing, shortness of breath), chest symptoms (chest tightness, chest pain) and cough. The ADSD was to be completed upon waking and refers to asthma symptoms during the night-time. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (None) to 10 (As bad as you can imagine). Higher scores indicate more severe symptoms. Mean daily scores of ADSD was calculated by weekly intervals. The baseline values were defined as the average score from Day -7 to Day -1 inclusive (at least 4 days must be non-missing). Change from Baseline was defined as value at each time point minus Baseline value.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Scores on a Scale
Change From Baseline in Asthma Daily Symptom Diary (ADSD) Weekly Mean Score at Week 52
Scores on a ScalePlaceboGSK3511294
Change From Baseline in Asthma Daily Symptom Diary (ADSD) Weekly Mean Score at Week 52-1.25 ± 0.140-1.33 ± 0.101
Statistical analysis
  • Placebo vs GSK3511294 · Mixed Models Repeated Measures (MMRM) · p = = 0.647 · Difference in least square means: -0.08 · 95% CI -0.42 to 0.26
SecondaryAnnualized Rate of Exacerbations Requiring Hospitalization and/or Emergency Department (ED) Visit up to 52 Weeks

The data did not meet the condition (total of 20 or more exacerbations requiring hospitalization and/or ED visit) for conducting the statistical analysis. The number of exacerbations requiring Hospitalization and/or ED Visit are reported here.

Time frame:
Up to Week 52
Reported as:
Number · Exacerbations
Annualized Rate of Exacerbations Requiring Hospitalization and/or Emergency Department (ED) Visit up to 52 Weeks
ExacerbationsPlaceboGSK3511294
Annualized Rate of Exacerbations Requiring Hospitalization and/or Emergency Department (ED) Visit up to 52 Weeks135

Adverse events

Collected over All-cause mortality, Serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected from the start of the study intervention (Day 1) till follow up week 56.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/132 (0%)22/132 (16.7%)78/132 (59.1%)
GSK35112940/250 (0%)15/250 (6%)145/250 (58%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventPlaceboGSK3511294
AsthmaRespiratory, thoracic and mediastinal disorders5/1323/250
PneumoniaInfections and infestations3/1321/250
COVID-19Infections and infestations2/1320/250
ArrhythmiaCardiac disorders1/1320/250
ColitisGastrointestinal disorders1/1320/250
PancreatitisGastrointestinal disorders1/1320/250
HerniaGeneral disorders1/1320/250
MassGeneral disorders1/1320/250
Bronchopulmonary aspergillosisInfections and infestations1/1320/250
Radius fractureInjury, poisoning and procedural complications1/1320/250
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlaceboGSK3511294
COVID-19Infections and infestations27/13251/250
NasopharyngitisInfections and infestations25/13229/250
Upper respiratory tract infectionInfections and infestations14/13225/250
InfluenzaInfections and infestations2/13219/250
RhinitisInfections and infestations10/13215/250
HeadacheNervous system disorders10/13212/250
Back painMusculoskeletal and connective tissue disorders7/1326/250
HypertensionVascular disorders7/1329/250
BronchitisInfections and infestations5/13212/250
Respiratory tract infectionInfections and infestations6/1328/250

Baseline characteristics

Full analysis set population included all randomized participants who received at least one dose of study intervention excluding participants from 1 site with GCP violation. Participants were analyzed according to the intervention they were allocated at randomization.

Age, Continuous
Age, Continuous(years)PlaceboGSK3511294Total
Mean53.6 ± 14.9154.1 ± 13.8253.9 ± 14.19
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGSK3511294Total
Female79144223
Male53106159
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboGSK3511294Total
White109207316
Others234366
08

Study locations

123 sites
  • GSK Investigational Site
    Encinitas, California 92024, United States
  • GSK Investigational Site
    Long Beach, California 90806, United States
  • GSK Investigational Site
    Pasadena, California 91105, United States
  • GSK Investigational Site
    Rancho Cucamonga, California 91730, United States
  • GSK Investigational Site
    San Jose, California 95117, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Loxahatchee Groves, Florida 33470-9272, United States
  • GSK Investigational Site
    Miami, Florida 33125, United States
  • GSK Investigational Site
    Miami, Florida 33144, United States
  • GSK Investigational Site
    New Port Richey, Florida 34655, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Alpharetta, Georgia 30022, United States
  • GSK Investigational Site
    Calhoun, Georgia 30103, United States
  • GSK Investigational Site
    Columbus, Georgia 31326, United States
  • GSK Investigational Site
    Savannah, Georgia 31406, United States
  • GSK Investigational Site
    Normal, Illinois 61761, United States
  • GSK Investigational Site
    Lexington, Kentucky 40509, United States
  • GSK Investigational Site
    Owensboro, Kentucky 42301, United States
  • GSK Investigational Site
    Rochester Hills, Michigan 48507, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89123, United States
  • GSK Investigational Site
    Bronx, New York 10459-2417, United States
  • GSK Investigational Site
    New York, New York 10036, United States
  • GSK Investigational Site
    Gastonia, North Carolina 28054, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Boerne, Texas 78006, United States
  • GSK Investigational Site
    Cypress, Texas 77099, United States
  • GSK Investigational Site
    Cypress, Texas 77429, United States
  • GSK Investigational Site
    Dallas, Texas 75235, United States
  • GSK Investigational Site
    Kerrville, Texas 78028, United States
  • GSK Investigational Site
    San Antonio, Texas 78258, United States
  • GSK Investigational Site
    Ajax, Ontario L1S 2J5, Canada
  • GSK Investigational Site
    Niagara Falls, Ontario L2H 1H5, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1G 6C6, Canada
  • GSK Investigational Site
    Windsor, Ontario N8X 1T3, Canada
  • GSK Investigational Site
    Quebec, G1G 3Y8, Canada
  • GSK Investigational Site
    Changchun, 130021, China
  • GSK Investigational Site
    Changchun, 132011, China
  • GSK Investigational Site
    Changsha, 410013, China
  • GSK Investigational Site
    Chengdu, 610041, China
  • GSK Investigational Site
    Guangzhou, 500000, China
  • GSK Investigational Site
    Guangzhou, 510115, China
  • GSK Investigational Site
    Guangzhou, 510120, China
  • GSK Investigational Site
    Guangzhou, 510150, China
  • GSK Investigational Site
    Hangzhou, 310009, China
  • GSK Investigational Site
    Hefei, 230001, China
  • GSK Investigational Site
    Hohhot, 010050, China
  • GSK Investigational Site
    Huhhot, 010017, China
  • GSK Investigational Site
    Jinan, 250014, China
  • GSK Investigational Site
    Sanya, 570311, China
  • GSK Investigational Site
    Shanghai, 200040, China
  • GSK Investigational Site
    Shanghai, 200065, China
  • GSK Investigational Site
    Shanghai, 200090, China
  • GSK Investigational Site
    Shenyang, 110004, China
  • GSK Investigational Site
    Shenyang, 110016, China
  • GSK Investigational Site
    Shenzhen, 518020, China
  • GSK Investigational Site
    Urumqi, 830054, China
  • GSK Investigational Site
    Wenzhou, 325000, China
  • GSK Investigational Site
    Wuhan, 430030, China
  • GSK Investigational Site
    Xi'an, 710061, China
  • GSK Investigational Site
    Xuzhou, 221006, China
  • GSK Investigational Site
    Zhanjiang, 524000, China
  • GSK Investigational Site
    Brno, 625 00, Czechia
  • GSK Investigational Site
    Hradec Kralove, 50333, Czechia
  • GSK Investigational Site
    Jindrichuv Hradec, 377 01, Czechia
  • GSK Investigational Site
    Olomouc, 779 00, Czechia
  • GSK Investigational Site
    Strakonice, 386 01, Czechia
  • GSK Investigational Site
    BesanCon, 25030, France
  • GSK Investigational Site
    Cholet, 49300, France
  • GSK Investigational Site
    Marseille, 13003, France
  • GSK Investigational Site
    Montpellier cedex, 34295, France
  • GSK Investigational Site
    Nice, 06001, France
  • GSK Investigational Site
    Tarbes cedex 9, 65013, France
  • GSK Investigational Site
    Aschaffenburg, 63739, Germany
  • GSK Investigational Site
    Berlin, 10367, Germany
  • GSK Investigational Site
    Frankfurt, 60389, Germany
  • GSK Investigational Site
    Hamburg, 22299, Germany
  • GSK Investigational Site
    Koblenz, 56068, Germany
  • GSK Investigational Site
    Leipzig, 04275, Germany
  • GSK Investigational Site
    Leipzig, 04357, Germany
  • GSK Investigational Site
    Magdeburg, 39120, Germany
  • GSK Investigational Site
    Mainz, 60549, Germany
  • GSK Investigational Site
    Neu-Isenburg, 63263, Germany
  • GSK Investigational Site
    Schleswig, 24837, Germany
  • GSK Investigational Site
    Cork, 00000, Ireland
  • GSK Investigational Site
    Dublin 9, D09 V2N0, Ireland
  • GSK Investigational Site
    Bergamo, 24127, Italy
  • GSK Investigational Site
    Milano, 20122, Italy
  • GSK Investigational Site
    Modena, 41124, Italy
  • GSK Investigational Site
    Pavia, 27100, Italy
  • GSK Investigational Site
    Roma, 00168, Italy
  • GSK Investigational Site
    Vicenza, 36100, Italy
  • GSK Investigational Site
    Kielce, 25-355, Poland
  • GSK Investigational Site
    Krakow, 30-033, Poland
  • GSK Investigational Site
    Lodz, 90-242, Poland
  • GSK Investigational Site
    Lublin, 20-552, Poland
  • GSK Investigational Site
    Strzelce Opolskie, 47-120, Poland
  • GSK Investigational Site
    Tarnow, 33-100, Poland
  • GSK Investigational Site
    Wroclaw, 53-201, Poland
  • GSK Investigational Site
    Wroclaw, 54-239, Poland
  • GSK Investigational Site
    Kemerovo, 650002, Russian Federation

Showing the first 100 of 123 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Nov 2023, 32 months.

Results were first posted in Dec 2024, 1 year after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 32 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2021
First posted
Jan 22, 2021
StartActual
Mar 17, 2021
Primary completionActual
Nov 21, 2023
CompletionActual
Nov 21, 2023
Results first posted
Dec 17, 2024
Last update
Dec 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04719832
Lead sponsor
GlaxoSmithKline
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Jan 22, 2021
Start date
Mar 17, 2021
Primary completion
Nov 21, 2023
Completion
Nov 21, 2023
Results posted
Dec 17, 2024
Last update
Dec 17, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Depemokimab

Start the discussion